NCT05710692 - Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2028

Conditions

Fabry Disease

Interventions

DRUG

PRX-102 1 mg/kg every 2 weeks

DRUG

PRX-102 2 mg/kg every 4 weeks

Trial Locations (9)

RECRUITING

Fukuoka University Chikushi Hospital, Chikushino-shi

RECRUITING

Tohoku University Hospital, Sendai

RECRUITING

University of the Ryukyu Hospital, Nishihara

RECRUITING

Osaka University Hospital, Suita

RECRUITING

Juntendo University Hospital, 3-1-3 Hongo, Bunkyo-ku, Tokyo, Bunkyo-ku

RECRUITING

Tokyo Jikei University Hospital, Minato-ku

RECRUITING

Keio University Hospital, Shinjuku-ku

RECRUITING

Asahikawa Medical University Hospital, Asahikawa

RECRUITING

Niigata University Medical & Dental Hospital, Niigata